|Day Low/High||4.90 / 5.05|
|52 Wk Low/High||4.34 / 10.00|
Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Egalet Corporation ("Egalet" or the "Company") (Nasdaq: EGLT).
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Egalet Corporation securities (NASDAQ: EGLT) from December 15, 2015 through January 9, 2017,...
Investors in Egalet Corp saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EGLT options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
--Company also issues options to new salesforce employees--
Levi & Korsinsky announces it has commenced an investigation of Egalet Corporation (NASDAQ:EGLT) ("Egalet") concerning possible violations of federal securities laws by the Company and/or certain of its officers and...
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
--Patent offers protection through February 2030--
--Company seeks to strengthen label with abuse-deterrent data that shows OXAYDO resists syringeability--
The worst appears to be over for this sector; we could see big growth ahead.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
No additional scientific information or data requested by FDA
The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 837,041 share increase in total short interest for Egalet Corp , to 3,618,284, an increase of 30.10% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
--Data presented today at PAINWeek 2016--
--An additional $40 million to be funded if ARYMO™ ER is approved by June 2017--
--Six posters to be presented including several highlighting abuse-deterrent profile of ARYMO™ ER and one on syringeability of OXAYDO®--